Phase 2 Study of Oral Belumosudil to Prevent Graft-Versus-Host Disease After Stem Cell Transplant in Adults with Blood Cancers

What this Trial Is About

Researchers are evaluating whether adding the drug belumosudil to the usual methods for preventing graft-versus-host disease GVHD can reduce GVHD risk in people with blood cancer who receive a stem cell transplant. This Phase II trial also aims to assess the safety of this approach. Participants have hematologic malignancies in remission and are at risk of developing GVHD after transplantation. Participants receive belumosudil, an oral drug that selectively inhibits ROCK2, as part of a GVHD prevention plan after their allogeneic hematopoietic cell transplant. The study is a single-group, open-label trial where all participants receive belumosudil after meeting specific criteria related to transplant timing and recovery. Treatment begins between 20 and 80 days post-transplant and continues under medical supervision. Throughout the study, participants are closely monitored with assessments including survival without GVHD or relapse at 1 year after transplant. Researchers evaluate blood counts, organ function, and adverse effects to ensure safety. Participants undergo regular clinical visits and laboratory tests to track their health and the drugs impact. The overall study duration extends up to the one-year primary outcome measurement after transplantation.

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant